Novavax:HC Wainwright Assumes Buy Rating, Sets PT at $10

Novavax:HC Wainwright Assumes Buy Rating, Sets PT at $10

H.C. Wainwright has upgraded Novavax (NVAX) to a Buy rating and set a price target of $10, according to a recent research note [3]. This marks a significant change from the previous Neutral rating and a price target of $9, which was set by the same firm in August 2025 [3].

The analyst at H.C. Wainwright cited several factors contributing to the upgrade. One key factor is Novavax's recent FDA approval for its protein-based COVID-19 vaccine, Nuvaxovid™, which has been the only non-mRNA option available in the U.S. [2]. The company has also transferred U.S. commercial leadership of Nuvaxovid™ to Sanofi, with authorization transfers for the U.S. and EU expected by the end of 2025 [2]. This partnership aims to broaden distribution and streamline logistics, potentially generating milestone payments for Novavax.

Additionally, Novavax's late-stage pipeline development and partnering efforts highlight the firm's shift from R&D focus to broader commercialization and global distribution. The company is leveraging its unique position as a non-mRNA vaccine provider in Western markets [2]. Early Phase 3 data show robust immune responses and improved T-cell activation compared with Fluzone HD, further bolstering the company's vaccine portfolio [2].

While the upgrade reflects a positive outlook on Novavax's prospects, it is essential to note that the stock's performance has been volatile, with analysts citing increasing competition and a "murky outlook" [3]. However, the recent upgrade suggests that H.C. Wainwright sees potential in Novavax's strategic initiatives and market position.

References
1. [1] https://www.tipranks.com/news/the-fly/buy-sell-wall-streets-top-10-stock-calls-this-week-thefly-14
2. [2] https://finance.yahoo.com/news/novavax-inc-nvax-launches-protein-090552441.html
3. [3] https://www.benzinga.com/quote/NVAX/analyst-ratings